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Abstract 
Background: Although mood disorders and cardiovascular diseases have widely studied psychosomatic connec‑
tions, data concerning the influence of the psychopathologically important affective temperaments in hypertension 
are scarce. To define a possibly higher cardiovascular risk subpopulation we investigated in well‑treated hypertensive 
patients with dominant affective temperaments (DOM) and in well‑treated hypertensive patients without dominant 
temperaments the level of depression and anxiety, arterial stiffness and serum Brain‑derived Neurotrophic Factor 
(seBDNF).
Methods: 175 hypertensive patients, free of the history of psychiatric diseases, completed the TEMPS‑A, Beck 
Depression Inventory and Hamilton Anxiety Scale questionnaires in two primary care practices. Of those 175 patients, 
24 DOM patients and 24 hypertensive controls (matched in age, sex and the presence of diabetes) were selected for 
measurements of arterial stiffness and seBDNF level.
Results: Beck and Hamilton scores in DOM patients were higher compared with controls. Pulse wave velocity and 
augmentation index did not differ between the groups while in the DOM patients decreased brachial systolic and 
diastolic and central diastolic blood pressures were found compared with controls. SeBDNF was lower in the DOM 
group than in the controls (22.4 ± 7.2 vs. 27.3 ± 7.8 ng/mL, p < 0.05).
Conclusions: Although similar arterial stiffness parameters were found in DOM patients, their increased depression 
and anxiety scores, the decreased brachial and central diastolic blood pressures as well as the decreased seBDNF 
might refer to their higher vulnerability regarding the development not only of major mood disorders, but also of 
cardiovascular complications. These data suggest that the evaluation of affective temperaments should get more 
attention both with regard to psychopathology and cardiovascular health management.
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Background
Mood disorders are common public health problem in 
the Western world and their strong connection to cardio-
vascular diseases (CVD) is well known [1]. Moreover, the 
negative impact of adverse individual psychological traits 
and characteristics, like anger, hostility and anxiety is also 
well-documented in connection to the development and 
progression of coronary heart disease [2, 3], while indi-
vidual differences in antagonism-related traits seem to 
predict a variety of cardiovascular outcomes [4, 5].
There are multiple mechanisms by which depression 
could increase the probability of vascular diseases, such 
as increased platelet activation [6], inflammatory mark-
ers [7] as well as reduced heart rate variability [8]. Parallel 
to this, well-established biomarkers of inflammation were 
also found to be elevated in persons in states of anger or 
hostility [9, 10], while a reduced function of the auto-
nomic nervous system was observed in states of anxiety 
[11] and interpersonal antagonism was connected with 
carotid arterial intima-media thickening [12].
Another possible link might be the brain-derived neu-
rotrophic factor (BDNF), a member of the neurotrophic 
factor family, which is not only associated with major 
depressive disorder [13], but its higher serum level is also 
connected to a decreased  risk  of cardiovascular disease 
and mortality [14].
The independent continuous relationship between ele-
vated blood pressure and several cardiovascular events 
is well-known for patients in all ages and ethnic groups 
[15]. Besides elevated blood pressure, arterial stiffening 
is increasingly recognised as a risk factor for CVD. The 
determination of decreased arterial elasticity helps to 
identify the patient’s higher risk of cardiovascular mor-
bidity and mortality [16]. In Europe, the measurement 
of arterial stiffness is already a recommended method 
for cardiovascular risk assessment among hypertensive 
patients [17]. Previously, depressive symptoms, especially 
in diagnosed depressive disorders were found to be asso-
ciated with increased arterial stiffening [18].
According to our recent findings, specific affective tem-
perament types (depressive, cyclothymic, hyperthymic, 
irritable and anxious) are the subclinical, trait-related 
manifestations and commonly the antecedents of minor 
and major mood disorders [19]. Recently, in a study of 
primary care patients we also demonstrated a strong con-
nection between dominant cyclothymic temperament 
and hypertension [20]. Moreover, we also showed that 
cyclothymic temperament is connected to acute coro-
nary events in hypertensive patients [21].
We hypothesised that hypertensive patients with 
dominant affective temperaments (DOM) score higher 
depression and anxiety values and have impaired arte-
rial stiffness, central blood pressure or serum BDNF 
compared with hypertensive patients without dominant 




In our cross-sectional case–control study well-treated 
chronic (>12 months medication) hypertensive Caucasian 
patients were investigated in two primary care practices. 
All patients completed the TEMPS-A, Beck Depression 
Inventory (BDI) and Hamilton Anxiety Scale (HAM-A) 
questionnaires in order to evaluate the presence of affec-
tive temperaments, depression and anxiety, respectively. 
Following this initial screening, patients with dominant 
affective temperaments (reaching the mean + 2 SD point 
scores or higher in each affective temperament subscale, 
DOM) were identified. Hypertensive controls without 
DOM, matched in age, gender and presence of diabetes, 
were selected from the initial hypertensive patient cohort 
and included in the arterial stiffness and seBDNF meas-
urements. As blood pressure medication can highly influ-
ence arterial stiffness, it was further analysed, but patients 
were not matched in this aspect.
Exclusion criteria were the history or ongoing treat-
ment of depression or anxiety (as with arterial stiffen-
ing the associations are clarified [18]), and the presence 
of atrial fibrillation or uncontrolled hypertension 
(>145/95  mmHg in repeated office measurements). 
In patients with an average blood pressure between 
140/90 and 145/95 mmHg in repeated office blood pres-
sure measurements, ambulatory 24-h blood pressure 
monitoring or home blood pressure monitoring was 
performed and only well-controlled patients were admit-
ted to the study. Prior to the participation, all patients 
gave their written informed consent. The study was 
approved by the Scientific and Research Ethics Commit-
tee of the Medical Research Council, Hungarian Min-
istry of Health (ETT TUKEB 842/PI/2011) and carried 
out in accordance with the tenets of the Declaration of 
Helsinki.
Procedures
During the initial visit patients completed the question-
naires. Physical examination (blood pressure, heart rate, 
height, weight and waist circumference) were completed 
and data on medical history (with special attention to 
cardiovascular risk factors, complications and depres-
sion) as well as on current medication was collected.
After the analysis of the questionnaires, patients meet-
ing the criteria of dominant temperament and their 
controls were invited for arterial stiffness and seBDNF 
measurements, which took place  within 1  month after 
the initial visit.
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Questionnaires
The temperament evaluation of Memphis Pisa, Paris and 
San Diego (TEMPS-A) questionnaire is an 110-item, 
self-report instrument, developed to measure affective 
temperaments on depressive, cyclothymic, hyperthymic, 
irritable and anxious subscales and requiring the answers 
‘yes’ (score 1) or ‘no’ (score 0) [22]. TEMPS-A is used to 
assess the point scores of each subscale and also to meas-
ure the presence of the dominant form of affective tem-
peraments by taking the mean of the subscale and adding 
up two standard deviations to it. Those reaching the 
mean + 2 SD level or higher in each subscale are consid-
ered to have dominant affective temperaments.
The beck depression inventory (BDI), created by Aaron 
T. Beck, is a 21-question multiple-choice self-report 
questionnaire, one of the widely used instruments for 
measuring the severity of depression. Participants are 
asked to make ratings on a four-point scale, where a 
higher score correlates with more severe depression.
Hamilton Anxiety Scale (HAM-A) was evaluated by the 
examiner to study the severity of anxiety. The scale con-
sists of 14 items, each item is scored on a scale of 0 (not 
present) to 4 (severe anxiety).
Arterial stiffness recordings
Measurements were performed in a temperature-con-
trolled room in supine position, on the day of blood sam-
pling, before it, between 7.00 and 8.00 a.m. Patients were 
required to fast overnight and refrain from smoking and 
caffeine-containing beverages before the procedure, but 
to take the usual blood pressure regulating medication. 
Upon arrival at the investigation unit, the subjects were 
equipped with measurement devices, and then rested in 
supine position for approximately 15  min before being 
measured. Arterial stiffness parameters were evaluated 
using the validated, gold-standard PulsePen tonometer 
(DiaTecne, Milan, Italy, [23]). With this method the pulse 
wave velocity (PWV) augmentation index (AI), as well as 
the central systolic blood pressure (central SBP) and cen-
tral pulse pressure (central PP) can be calculated. In each 
subject two sequences of measurements were performed 
and their mean was used for statistical analysis. ECG was 
recorded continuously from the limb lead with the largest 
R wave.
In the PWV calculations 80  % of the carotid-femoral 
distance was used, following the recent guideline [24]. 
Previously we evaluated the intra- and interobserver vari-
abilities of PWV measurements obtained by the PulsePen 
device on hypertensive patients and found them to be 
4.6 and 6.3  % high, respectively. As PulsePen calculates 
pressure values using brachial diastolic blood pressure 
calibration, the calculated central and brachial diastolic 
blood pressure values were identical [23].
Measurement of seBDNF concentration
Peripheral blood samples of patients were collected in 
anticoagulant-free tubes, right after the measurement 
of arterial stiffness. After centrifugation (3600  rpm 
for 6  min) the serum was stored at −20  °C. SeBDNF 
was measured using commercially available sandwich 
enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis MN, USA) according to the manufacturer’s 
protocol and serum BDNF level was determined in ng/
mL.
Data analysis
Data were expressed as mean ± SEM and medians. Dif-
ferences in variables between controls and DOM patients 
were analysed using unpaired Student’s t tests or Mann–
Whitney rank-sum tests for data failing tests of normal-
ity. Blood pressure medications were calculated and 
compared using equivalent doses, differences were ana-
lysed with unpaired Student’s  t  tests or Mann–Whitney 
rank-sum tests. Significance was accepted at p  <  0.05. 
Statistical analysis was performed using the SigmaStat for 
Windows Version 3.5 (SPSS) program package.
Results and discussion
Characteristics of the patients
183 hypertensive patients were recruited to participate in 
the study and 175 of them completed the questionnaires. 
29 of the patients had dominant affective temperaments 
(DOM). Out of the 29 DOM patients one died 3  days 
prior to the planned arterial stiffness measurement and 
four declined to further participate in arterial stiffness 
measurements. The arterial stiffness and BDNF of alto-
gether 48 hypertensive patients was evaluated: 24 DOM 
and 24 control subjects matched in age, gender and pres-
ence of diabetes.
Among the DOM patients six subjects with depres-
sive, five irritable and four anxious dominant tempera-
ments were found. In the other patients, combinations 
of dominant temperaments were present: three patients 
had cyclothymic and depressive, two had cyclothymic 
and irritable, two had cyclothymic, depressive and anx-
ious, one had cyclothymic, irritable and anxious temper-
aments and one patient was dominant for cyclothymic, 
irritable, anxious and depressive affective temperaments. 
No patient with a dominant hyperthymic temperament 
was found in our cohort.
Comparing the control and DOM patients for statistical 
differences
Baseline demographic, anthropometric and laboratory 
parameters and the used cardiovascular medications of the 
patients are presented in Table 1. SeBDNF levels were lower 
in DOM patients. Compared with controls, beta-blockers 
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were prescribed more frequently and in higher dose in the 
DOM group [0.63 (0–5) vs. 5 (0.63–6.88) mg, calculated 
for bisoprolol, respectively, p < 0.05]. No differences were 
found in the mean duration of hypertension among con-
trols and DOM patients [10.5 (4–15.8) vs. 12 (6.5–17.8) 
p = 0.238, respectively]. No differences were found among 
the groups studied in smoking habits and in the frequency 
of physical training (data are not shown).
Table  2 represents the differences in the five affective 
temperaments and in the BDI and HAM-A scores. Com-
pared with controls, in DOM patients depressive, cyclo-
thymic, irritable and anxious scores were higher, while 
hyperthymic scores were equal. Both BDI and HAM-A 
scores were markedly higher in DOM patients than in the 
controls.
Brachial and central hemodynamic and arterial stiff-
ness parameters are shown in Table  3. Brachial systolic 
and both brachial and central diastolic and mean blood 
pressures were lower in DOM patients. PWV and AI, 
the two main arterial stiffness parameters, did not differ 
when compared with controls.
Our pilot study was performed on hypertensive 
patients with dominant cyclothymic, irritable, depressive 
or anxious affective temperaments without the history 
or any present psychiatric medications. We found that 
DOM patients had higher anxiety and depression scores 
and lower seBDNF level. DOM patients had similar levels 
of arterial stiffening with a lower peripheral and central 
blood pressure compared with hypertensive controls.
Table 1 Baseline demographic, anthropometric and  labo-
ratory parameters and the used cardiovascular medication 
of the patients
The values are mean ± SEM or medians (quartiles)
The groups were compared for differences by using Student’s t test or the 
Mann–Whitney rank-sum for data failing tests of normality
DOM patients with dominant affective temperament, AC abdominal 
circumference, BMI body mass index, CKD-EPI GFR glomerular filtration rate 
assessed by the chronic kidney disease epidemiology collaboration glomerular 
filtration rate equation; BDNF: brain-derived neurotrophic factor, ARBs 
angiotensin II receptor blockers
* p < 0.05 compared with controls
Control DOM
N (male:female) 24 (9:15) 24 (9:15)
Age (year) 63.7 ± 2.54 64.3 ± 2.52
Body height (cm) 164.5 ± 1.51 166 ± 2.06
Body weight (kg) 76.3 ± 2.66 81 ± 3.34
AC (cm) 101.5 ± 4.1 102 ± 5.5
BMI (kg/m2) 28.2 (26–31.2) 29.8 (24.4–34.6)
Glucose (mmol/l) 5.36 (5.03–6.07) 5.7 (4.94–6.63)
CKD‑EPI GFR (mmol/l) 77.5 (62.5–86) 78.5 (60.8–90)
Uric acid (µmol/l) 309.3 ± 15.26 321.6 ± 16.82
Cholesterol (mmol/l) 5.48 ± 0.22 5 ± 0.35
Triglyceride (mmol/l) 1.36 (1.08–2.18) 1.82 (0.99–2.15)
BDNF (ng/ml) 27.29 (24.2–30.35) 20.10 (14.74–27.11)*
ACE‑inhibitors [n (%)] 13 (54.2) 13 (54.2)
ARBs 9 (37.5) 5 (20.8)
Calcium‑channel blockers 11 (45.8) 11 (45.8)
Beta‑blockers 12 (50) 18 (75)*
Diuretics 11 (45.8) 11 (45.8)
Antiplatelet medication 8 (33.3) 11 (45.8)
Table 2 TEMPS-A scores of  affective temperaments, BDI 
and HAM-A scores
The values are mean ± SEM and medians (quartiles). The groups were compared 
for differences by using Student’s t test or the Mann–Whitney rank-sum for data 
failing tests of normality
DOM patients with dominant affective temperament, TEMPS-A the temperament 
evaluation of Memphis Pisa, Paris and San Diego questionnaire, BDI beck 
depression inventory, HAM-A Hamilton Anxiety Scale





Depressive 6 (4.25–8.75) 12.5 (7–13.75)*
Cyclothymic 3 (1–5) 9.5 (7–13.75)*
Hyperthymic 12.13 ± 0.73 10.46 ± 0.99
Irritable 2 (1–4.75) 9.5 (5–11)*
Anxious 5.08 ± 0.81 14.67 ± 0.88*
BDI 5 (2–7.75) 14.5 (8.5–19.75)*
HAM‑A 7 ± 1.27 16.67 ± 1.68*
Table 3 Brachial and  central hemodynamic and  arterial 
stiffness parameters
The values are mean ± SEM and medians (quartiles). The groups were compared 
for differences by using Student’s t test or the Mann–Whitney rank-sum for data 
failing tests of normality
DOM patients with dominant affective temperament, HR heart rate, SBPB systolic 
brachial blood pressure, DBPB diastolic brachial blood pressure, MBPB mean 
brachial blood pressure, PPB brachial pulse pressure, Central SBP central systolic 
blood pressure, Central DBP central diastolic blood pressure, Central MBP central 
mean blood pressure, Central PP central pulse pressure, PWV pulse wave velocity, 
AI Augmentation index





HR (1/min) 66 ± 1.25 63.1 ± 1.17
SBPB (Hgmm) 130.8 (122–137.1) 122.6 (116.4–129.7)*
DBPB (Hgmm) 71.2 ± 1.5 66.6 ± 1.71*
MBPB (Hgmm) 91.9 ± 1.53 86.6 ± 1.94*
PPB (Hgmm) 59.3 (49.4–67.5) 54.3 (50.1–61.9)
Central SBP (Hgmm) 124.3 (113.5–136.4) 117 (112.6–131.7)
Central DBP (Hgmm) 71.2 ± 1.5 66.5 ± 1.71*
Central MBP (Hgmm) 94.1 ± 1.55 88.9 ± 1.96*
Central PP (Hgmm) 50.6 (44.5–66.6) 52.3 (48.8–1.72)
PWV (m/s) 9.32 (8.02–11.25) 8.74 (8.32–9.87)
AI (%) 16.04 ± 2.24 14.54 ± 2.66
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Affective temperaments are associated with depression 
and anxiety
Affective temperaments are tightly related to affective 
disorders. Hyperthymic temperament was found to be 
associated with type-I and cyclothymic with type-II bipo-
lar disease [25] and atypical depression [19, 26], depres-
sive temperament, in contrast to this, with unipolar 
major depression [19, 27]. In our cohort DOM patients 
also had higher depression and anxiety scores suggesting 
the importance of a joint evaluation of affective tempera-
ments together with depression and anxiety even in those 
hypertensive patients who have no records of previous 
psychiatric diseases or any present antidepressant or 
anxiolytic medication.
Affective temperaments and cardiovascular risk
Although the presence of dominant affective tempera-
ments frequently precedes the onset of minor and major 
affective illness [19], and therefore screening for their 
presence would be an important target in the prevention 
and early intervention of cardiovascular disorders as well, 
only few studies are available which aim to investigate the 
role of affective temperaments in the development and 
risk of different cardiovascular diseases. Patients with 
depressive temperament were found to have worse meta-
bolic control in type-2 diabetes [28], while cyclothymic, 
irritable and anxious temperaments showed affinity to 
obesity [29]. Recently we evaluated the role of affective 
temperaments in primary hypertension and found a sig-
nificant association with the dominant cyclothymic tem-
perament [20]. Moreover, cyclothymic temperament was 
associated with acute coronary events in hypertensive 
patient population [21]. In our present study, patients 
with affective temperaments had lower brachial and 
central diastolic and mean blood pressure values than 
controls. It is well known that decreased diastolic blood 
pressure is associated with increased mortality [30]. Par-
allel to our previous findings in hypertensive patients 
mentioned above [20, 21], this phenomenon of decreased 
blood pressure values might be more expressed in cyclo-
thymic patients and would in this case suggest their 
increased susceptibility to cardiovascular complications. 
However, the clarification of this hypothesis requires fur-
ther studies.
As our DOM patients had higher depression score 
compared with control patients, one explanation of the 
decreased blood pressure might reflect the fact that lower 
blood pressure levels are often accompanied by a pro-
nounced presence of depressive symptoms and in follow-
up studies symptoms of anxiety and depression predicted 
the development of lower blood pressure [31, 32]. In 
case of a co-occurring onset of depression and hypoten-
sion, the pathophysiological mechanisms are considered 
to be the alterations in neurohormonal, immune and 
autonomic regulations [33]. Whether only the increased 
depression per se caused the decreased blood pressure in 
our DOM patients, or another independent factor is also 
involved, is a question still to be answered.
Most of the studies support the idea that antagonistic 
traits, depression and anxiety increase the probability of 
the development of cardiovascular diseases [12, 34, 35], 
and data are also available with respect to arterial stiff-
ness. In their population-based, cross-sectional study 
including 3704 elderly patients, Tiermeier et  al. found 
that patients with increased arterial stiffness were more 
likely to have depressive symptoms. The association was 
stronger in cases with diagnosed depressive disorders. 
The authors concluded that arterial stiffness may partly 
cause the proposed relationship between vascular fac-
tors and depression [18]. In contrast to this we found no 
difference in PWV or augmentation index between our 
DOM and control hypertensive patients. An explanation 
to this phenomenon can be that in the study of Tiermeier 
et  al. the patients’ arterial stiffness was much higher, as 
the border of the lowest PWV quartile was 11.4 m/s. This 
suggests a very poor vascular status of those patients, 
while in our patients PWV values were much lower.
In a recent study of Seldenrijk et  al., depression and 
anxiety sensitivity and their association with arterial 
stiffening were evaluated. The authors found that out of 
these only anxiety sensitivity was associated with arterial 
stiffness; however, they studied only the augmentation 
index, which is a more variable parameter compared to 
PWV and is influenced by resistance vessels, that can be 
dysfunctional in patients with anxiety [36, 37]. It is also 
worth mentioning that the population of Seldenrijk et al. 
was much younger (46  years) compared with ours and 
only 18 % of the patients regularly took antihypertensive 
medication which suggests their better general resistance 
vessel function. Considering all these results we suppose 
that in older patients besides optimal vascular therapy, 
the deleterious effects of depression and anxiety for arte-
rial stiffening can be attenuated, but in younger popula-
tion without vascular medication the deleterious effects 
of anxiety can lead to detectable dysfunction of resistance 
vessels in comparison to healthy controls.
Serum BDNF level, affective temperaments and allostatic 
load
In our study seBDNF, too, was measured and we 
observed its decreased level in our DOM patients. 
SeBDNF was found to be lower in patients suffering 
from major depressive disorder and some types of anxi-
ety disorders, while in animal models the regulation of 
BDNF was suggested to contribute both to anxiety-like 
behaviour and hypertension [38–40]. BDNF was found 
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to be decreased also in such pathological conditions as 
acute coronary syndrome and type 2 diabetes [41, 42]. 
Whether the decreased seBDNF in our hypertensive 
DOM patients is correlated with their higher depression 
and anxiety and bears any clinical relevance with respect 
to the cardiovascular outcome or not, further studies 
need to clarify.
The term “allostatic load” refers to a cumulative, mul-
tisystem view of the physiologic toll that is required for 
adaptation to stress. In mood disorders, especially in 
bipolar disorder allostatic load increases progressively 
as mood episodes occur over time [43]. Among many 
mediators, neurotrophic factors such as decreased level 
of BDNF indicates allostatic load [44]. Seeman et  al. 
found in their longitudinal, community-based study that 
allostatic load may play a role in cardiovascular disorders 
[45] and there is evidence that reduction in allostatic 
load is associated with lower all-cause mortality, even 
in geriatric patients [46]. As affective temperaments 
are the subclinical manifestations of minor and major 
mood disorders and we found decreased BDNF level in 
patients with dominant temperaments, it can indicate an 
increased allostatic load among them, as well. Accord-
ing to this theory the increased cardiovascular risk could 
also be explained with the phenomenon of allostatic 
load.
In our study the depressive, cyclothymic, irritable and 
anxious temperaments or their combinations were inves-
tigated together. The neurobiological background of 
these temperaments seems to be at least partly common, 
as all were found to be associated with the 5-HTTLPR 
polymorphism of the serotonin transporter gene, namely 
the presence of the s allele, which is connected with 
decreased serotonin uptake of cells [47]. Moreover, the 
scales of depressive, anxious, cyclothymic and irritable 
temperaments were found to be closely associated in 
different populations suggesting real phenotypical con-
nections beyond the similarities in the neurobiological 
background [48, 49]. Whether the clustering of dominant 
temperaments has any pronounced clinical relevance 
above single dominant temperaments is another question 
to be answered.
Risk stratification of hypertensive patients
The calculation of total cardiovascular risk of hyperten-
sive patients is a very important task of hypertension care 
[17]. Our results support the possibility that in the future 
the evaluation of affective temperaments might be the 
part of the risk stratification procedure of hypertensive 
patients as besides the obvious connection with mood 
disorders, the identification of DOM patients could 
determine a higher cardiovascular risk patient popula-
tion as well.
Limitations
The main limitation of our study is the relatively low 
number of patients involved. Out of 183 invited hyper-
tensive patients, the arterial stiffness parameters of only 
24 subjects with dominant affective temperament and 
24 controls were analysed. The low number of patients 
limits the generalisability of our data and type I and type 
II errors cannot be excluded. As the detailed analysis of 
the impact of unique dominant affective temperaments 
on arterial stiffness, central blood pressure or seBDNF 
require higher number of involved patients, we defined 
this study as a “pilot”. Another limitation comes from 
the cross-sectional design of the study which precludes 
causal inference.
Conclusions
In conclusion, although arterial stiffness parameters did 
not differ between the DOM subgroup of well-treated 
hypertensive patients and their hypertensive controls, 
their higher depressive and anxious scores and lower 
seBDNF might reflect their higher susceptibility for car-
diovascular complications. Furthermore, DOM patients 
might bear a higher risk, as they have lower brachial and 
central diastolic blood pressure values in comparison to 
patients without dominant temperaments. The clinical 
significance of our findings with respect to the cardio-
vascular outcome of these patients needs further exami-
nations on higher number of patients involved, but the 
cumulating data suggest that the evaluation of affective 
temperaments might improve both psychopathological 
and cardiovascular risk stratification.
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